Medtronic Announces Onset of Onyx ONE Clear study in High Bleeding Risk Patients with Resolute Onyx DES

 Medtronic Announces Onset of Onyx ONE Clear study in High Bleeding Risk Patients with Resolute Onyx DES

Medtronic Announces Onset of Onyx ONE Clear study in High Bleeding Risk Patients with Resolute Onyx DES

Shots:

  • Onyx ONE Clear study will assess one-month DAPT in high bleeding risk patients implanted with the Resolute Onyx DES in the US and Japan evaluating its safety i.e. risk of cardiac death, heart attack and stent thrombosis
  • Onyx ONE Clear is similar to Onyx ONE Global Study, involving administration of (aspirin + an anti-clotting medication) followed by PCI with Resolute Onyx DES, combine to form Onyx ONE Month DAPT Program (N=~2700) with 140 sites WW
  • This study will assist in understanding insights of patients at high risk of bleeding, and with unexpected bleeding occurrence also help in meeting the unmet needs of patients
  • With more than 20,000 patients have undergone DAPT duration trials. Resolute Onyx DES received CE Mark in Sept, 2014 with FDA approval in April ,2017

Click here to read full press release/ article | Ref: Medtronic | Image:  AV Stumpfl

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post